WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
World Federation of Hemophilia shared on LinkedIn:
”The WFH has released new evidence-based guidelines on AAV gene therapy for hemophilia, covering eligibility, center readiness, infusion safety, and long-term monitoring.
A major step forward for people with bleedingdisorders.
Find out more”
The World Federation of Hemophilia (WFH) has released a new evidence-based clinical practice guideline focused on adeno-associated virus (AAV) gene therapy for people with hemophilia (PwH).
This marks the addition of a dedicated gene therapy section within the broader WFH Guidelines for the Management of Hemophilia.
The guideline offers practical, up-to-date recommendations to support clinicians and patients in navigating this rapidly advancing treatment landscape.
It aims to promote safe, informed, and equitable use of gene therapy across the global bleeding disorders community.
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 12:46Rosa Hart: Inside Pediatric Stroke Recovery with Dr. Catherine Schuster
-
Apr 14, 2026, 12:39Gonzalo Ladreda: Innovation in Stroke Care Is About Timing, Integration, and Real-World Usability
-
Apr 14, 2026, 12:30Roy P.C. Kessels: Stroke’s Cognitive Impact on Young Adults Is Significant and Often Overlooked
-
Apr 14, 2026, 12:22Mehari Gebreyohanns: New Insights on Wake-Up Strokes from Emergency Settings in Texas and Louisiana
-
Apr 14, 2026, 12:08Enrico Ferro: Comparative Study Raises Questions on PFA Safety in AF at EHRA 2026
-
Apr 14, 2026, 11:39Prachi Patel: How B Vitamins and Large-Scale Research Are Shaping Stroke Prevention
-
Apr 14, 2026, 11:28Jamie Brannigan: Help Shape the Future of Brain-Computer Interfaces in Stroke and Neurological Care
-
Apr 14, 2026, 11:18David Ferri: A Fontan Conduit Thrombosis Managed With an Innovative Catheter-Based Thrombectomy
-
Apr 14, 2026, 09:51Understanding Bleeding Disorder of Unknown Cause – EHC